ArticleERJ open research2026
Epidemiology, risk factors and clinical outcome of community-acquired pneumonia in severely immunosuppressed patients: a comprehensive analysis from the multinational, prospective CAPNETZ Cohort.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite growing evidence that immunosuppression (IS) influences aetiology and prognosis of community-acquired pneumonia (CAP), there remains a lack of data from representative multicentre studies. Methods: The multinational prospective CAPNETZ study includes patients with CAP and HIV since 2017, and with other causes of IS since 2020. We present the first comprehensive analysis of patients with CAP and IS (HIV with low CD4 cells, systemic steroids, immunosuppressive drugs, antineoplastic treatment, neutropenia, primary immunodeficiency, transplantation, haematological neoplasia) included within CAPNETZ until December 2023. IS cases were matched 1:1 with non-IS patients. The primary end-point was 30-day mortality and/or organ replacement therapy. Additionally, cases of CAP caused by non-core respiratory pathogens (NCRPs) according to an international consensus were evaluated. Univariate and multivariate risk factor analyses and evaluation of predictive scores by receiver operating characteristic analysis were performed. Results: We included 232 patients with IS, most commonly after antineoplastic therapy (37.5%), systemic steroids (36.2%) and immunosuppressive drugs (35.8%). 10.3% reached the primary end-point. Overall, IS was not associated with prognosis compared to matched non-IS patients, but patients with immunosuppressive drugs had a significantly lower risk. The qSOFA, CRB-65 and CURB-65 scores showed limited prediction (area under the curve 0.57-0.64) and insufficient sensitivity for the primary end-point. CAP caused by NCRPs occurred in 16.4% in IS and was associated with transplantation, previous anti-infective treatment and intensive care unit admission, but SARS-CoV-2, Conclusion: This study demonstrates the relevance and heterogeneity of CAP in IS and highlights the need for individualised risk stratification and treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.